<?xml version="1.0" encoding="UTF-8"?>
<p>Convalescent plasma therapy has also been used for treating coronavirus diseases such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). A study from a hospital in Hong Kong evaluated the efficacy of convalescent plasma therapy in the treatment of patients with SARS in 2003 [
 <xref rid="B15" ref-type="bibr">15</xref>]. A higher day-22 discharge rate was observed among patients who were given convalescent plasma before Day 14 of illness and among those who were PCR positive and seronegative for coronavirus at the time of plasma infusion. During the MERS epidemic in South Korea, convalescent plasma therapy was performed for several MERS patients, and a study suggested that donor plasma with a neutralization activity of a plaque reduction neutralization test (PRNT) titer â‰¥1:80 should be used for convalescent plasma therapy [
 <xref rid="B16" ref-type="bibr">16</xref>].
</p>
